The U.S. diagnostic imaging market is valued at approximately $150 billion in 2025 and encompasses an estimated 600 million or more procedures annually. But where a scan is performed matters enormously — for the patient’s bill, the provider’s bottom line, and the trajectory of healthcare spending.

Diagnostic imaging is delivered across four distinct facility types: hospital-based radiology departments, freestanding imaging centers, urgent care clinics, and mobile imaging providers. Each operates with a different business model, cost structure, clinical capability, and growth trajectory. Three forces are converging to reshape this landscape: imaging volume migrating from hospitals to lower-cost outpatient settings, federal reimbursement policy targeting the pricing gap between facility types, and private equity investment accelerating consolidation among independent providers.

Hospital-Based Radiology: The Dominant Incumbent

Hospital radiology departments perform the majority of all U.S. imaging volume and offer the broadest clinical capability of any facility type — full-spectrum modality suites including MRI, CT, X-ray, ultrasound, PET/CT, mammography, fluoroscopy, nuclear medicine, and interventional radiology. Imaging contributes a substantial amount to outpatient profit for many hospital systems, making it arguably their single most important outpatient revenue engine.

The financial mechanics are distinctive. Hospital outpatient departments (HOPDs) generate two separate charges — a facility fee and a professional fee — which is why the same scan costs dramatically more at a hospital than elsewhere. HOPD imaging prices can run significantly higher compared to freestanding centers. A procedure costing $600 at an independent center can range from $1,000-1,800 at a hospital.

This pricing advantage is under sustained policy pressure. CMS has expanded site-neutral payment cuts across multiple service categories, and the CY 2026 OPPS rule finalized site-neutral rates for drug administration services. More consequentially, CMS has formally requested information on extending site-neutral payment to imaging without contrast — signaling that diagnostic imaging reimbursement reform may be next. The Congressional Budget Office projects comprehensive site-neutral reform could save $157 billion over ten years.

In response, many health systems are building or acquiring freestanding outpatient imaging centers through joint ventures with established operators, seeking to capture volume migrating to lower-cost settings while a growing share of major imaging center chains become hospital-owned or affiliated.

Freestanding Imaging Centers: The Market’s Growth Engine

Freestanding imaging centers in the U.S. handle the second most imaging volume and generate an estimated $24-27 billion in annual revenue. Their defining competitive advantage is cost: they typically charge 40–65% less than hospitals for equivalent procedures, with no facility fee, lower overhead, higher equipment utilization, and a single transparent bill.

Most centers operate MRI, CT, X-ray, ultrasound, and mammography, with some offering PET/CT. They generally do not handle emergencies, complex interventional procedures, or integrated inpatient workflows — their sweet spot is scheduled outpatient imaging.

The ownership landscape for freestanding centers is evolving rapidly. RadNet, the largest publicly traded provider, operates 418 centers and reported record 2025 revenue of $2.04 billion. Private equity has become a dominant force beyond RadNet: SimonMed Imaging (170+ locations), RAYUS Radiology (140 fixed sites), Capitol Imaging Services (57+ locations), and Envision Radiology (100+ locations after acquiring Rezolut in late 2025) are all PE-backed. By the end of 2023, 12% of all U.S. radiologists were PE-employed — up from just 1% a decade earlier.

Urgent Care and Retail Clinics: A Narrow but Expanding Role

As of mid-2025, nearly 12,000 active urgent care clinics operate in the U.S., with the market estimated to be $34-38 billion in annual revenue. About 90% offer digital X-ray, but capabilities drop off sharply beyond that — ultrasound is available at an estimated 2- 10% of centers, CT at fewer than 2%, and MRI is essentially absent. Retail clinics like CVS MinuteClinic generally do not offer imaging at all.

Urgent care fills a useful but limited niche: speed and convenience for a quick X-ray to rule out a fracture. For anything beyond basic radiography, it serves as a triage point referring patients to hospitals or freestanding centers.

Mobile Imaging: Bringing the Scanner to the Patient

Mobile imaging providers bring MRI, CT, PET/CT, mammography, and X-ray equipment on specially outfitted trucks directly to facilities that need them. The U.S. mobile imaging market is estimated to be growing at roughly 4.5% annually.

The model is contract-based — hospitals, nursing homes, and rural clinics that cannot justify permanent installations contract for scheduled imaging days. Akumin (owned by Stonepeak) operates the nation’s largest mobile fleet, serving over 800 hospitals across 46+ states after its $820 million acquisition of Alliance HealthCare Services. Shared Medical Services recently deployed the first mobile helium-free MRI and TridentCare sends portable X-ray and ultrasound equipment to patients’ bedsides in nursing homes and assisted living facilities, serving 5,000+ locations.

Mobile imaging’s greatest value is access. Dana-Farber Cancer Institute’s mammography van has screened over 24,000 women since 2002, predominantly from underserved communities. MRI is the largest mobile revenue category at 37% of the market, while PET/CT and Ultrasound are the fastest growing subsegments.

The Forces Reshaping Every Arena

Four cross-cutting forces will shape the industry’s trajectory. Reimbursement reform favors lower-cost settings as CMS expands site-neutral policies, with imaging explicitly in the crosshairs. Workforce shortages are acute, a significant number of the nation’s estimated 41,000 radiologists are over 55, and technologist vacancy rates hit all-time highs in 2025 (CT at 19.4%, MRI at 17.4%). AI adoption is becoming a competitive differentiator, with over 1,250 FDA-authorized AI medical devices in radiology and large operators like RadNet’s DeepHealth subsidiary investments approaching $600 million in AI acquisitions. Consolidation continues to accelerate, with PE completing over a dozen imaging deals in 2025 and health systems acquiring outpatient centers to retain migrating volume.

Conclusion

The U.S. diagnostic imaging market is four overlapping arenas with distinct economics and competitive positions. Hospitals offer unmatched breadth but face mounting reimbursement pressure. Freestanding centers are the growth engine, powered by 50%+ cost advantages and PE investment. Urgent care adds imaging at the margins. Mobile fills critical access gaps for underserved populations.

The forces ahead — site-neutral reform, AI capability, workforce constraints, and consolidation — favor scale, capital efficiency, and adaptability. The providers that navigate this convergence most effectively will capture disproportionate share of a market on track to exceed $240 billion within the next decade.

The diagnostic imaging industry is continuing to see significant technological innovation. Across CT, MRI, and ultrasound, OEMs are bringing innovations to market that don’t just improve image quality — they have the potential to change where, how, and by whom imaging is performed. Three key forces driving this transformation are: the pursuit of higher diagnostic precision, the imperative to expand access, and the deepening integration of artificial intelligence.

CT: Photon-Counting Technology Enters the Mainstream

The most significant recent innovation in CT is the arrival of photon-counting detector technology (PCCT). Unlike conventional CT, which converts X-rays into light before measurement, PCCT directly counts individual X-ray photons and records their energy. The result is higher spatial resolution, lower radiation doses, and more spectral information available in every scan.

Siemens Healthineers was first to market in this space. Since launching the NAEOTOM Alpha in 2021 — the world’s first commercial photon-counting CT — over one million patients have been scanned worldwide. In March 2025, the FDA cleared the expanded NAEOTOM Alpha class, adding the dual-source Alpha.Pro and the single-source Alpha.Prime, which brings this technology to a broader range of facility types. Siemens has committed $86 million to expanding photon-counting detector production at its Forchheim, Germany facility.

The competitive landscape is shifting. In November 2025, GE HealthCare submitted a 510(k) to the FDA for its Photonova Spectra system, built on proprietary Deep Silicon detector technology featuring 8-bin energy resolution. GE states the system is designed to capture up to 50 times more data than conventional CT models. Canon Medical Systems and NeuSoft have also displayed photon-counting systems, signaling a transition from single-vendor technology to a multi-vendor competitive market.

MRI: Helium-Free Systems and Portability Expand Access

In MRI, one stream of innovation is focused on removing the barriers that have historically limited where systems can be installed and operated — most notably, the dependency on liquid helium.

Conventional MRI systems require from 1,500 to 1,800 liters of helium for superconducting magnet cooling. A new generation of systems is eliminating that dependency, and all three major OEMs are now competing in this space.

Philips has the longest track record, having pioneered its BlueSeal helium-free magnet technology since 2018. With more than 2,000 BlueSeal 1.5T systems installed worldwide, Philips says the technology has saved over 6 million liters of liquid helium to date. At RSNA 2025, the company unveiled BlueSeal Horizon — the industry’s first helium-free 3.0T MRI platform — which encloses just 7 liters of helium permanently in the cryogenic circuit, eliminating the need for refills or vent pipes.

Siemens Healthineers’ MAGNETOM Flow Platform uses DryCool technology with just 0.7 liters of helium in a sealed-for-life design, requiring no helium refills and no quench pipe, all within a 25-square-meter footprint. In June 2025, the FDA cleared the Magnetom Flow.Ace, Siemens’ first helium-free 1.5T system, which the company says reduces annual energy consumption by more than 30% versus the prior generation. GE HealthCare also entered the space at RSNA 2025 with Signa Sprint with Freelium, a ventless 1.5T system using less than 1% of the helium required by conventional MRI.

In another innovation stream, portable MRI is gaining clinical traction. In June 2025, the FDA cleared Hyperfine’s next-generation Swoop system, an AI-powered portable brain MRI weighing just 630 kg that plugs into a standard wall outlet. Early clinical users have reported image quality comparable to head CT — a notable benchmark for a device operating at 0.064 Tesla.

Meanwhile, Philips received FDA clearance for SmartSpeed Precise, which the company describes as the industry’s first integrated dual-AI MRI solution, delivering up to 3x faster scanning and up to 80% sharper images across its 1.5T and 3T installed base.

Ultrasound: The Point-of-Care Revolution

One key area of Ultrasound innovation is defined by miniaturization and intelligence. Ultrasound form factors have expanded from cart-based systems to include smartphone-sized handhelds — exemplified by GE HealthCare’s Vscan Air, Philips’ Lumify, and Butterfly Network’s single-probe whole-body imager. These devices are making diagnostic imaging available at the bedside, in the ambulance, and in rural clinics where traditional imaging infrastructure doesn’t exist.

AI is a central differentiator. Embedded algorithms now assist with image acquisition, automated measurements, and real-time clinical decision support, lowering the skill barrier for non-specialist clinicians. At RSNA 2025, GE HealthCare showcased early-stage concepts for autonomous ultrasound workflows developed in collaboration with NVIDIA.

The Common Thread: AI Across All Modalities

AI is not a feature bolted onto imaging systems — it is becoming embedded in the core imaging chain. As of late 2025, the FDA has authorized more than 1,350 AI-enabled medical devices, with radiology accounting for approximately 77% of all authorizations — surpassing 1,000 radiology AI devices for the first time. Every major OEM now offers native AI capabilities: Siemens’ myExam Companion, GE’s AIR Recon DL, Philips’ SmartSpeed Precise, and Hyperfine’s Optive AI.

What These Innovations Signal

These are compelling innovations occurring across multiple modalities in the same time period. Photon-counting CT is transitioning from a one-vendor novelty to a competitive battleground. Helium-free and portable MRI are lowering installation and operating barriers, opening new addressable settings. Handheld ultrasound is redefining point-of-care diagnostics. And AI is the connective tissue accelerating all three.

With these innovations the diagnostic imaging landscape continues to evolve and provide better information, in more places, and in a format which is accessible to more practitioners and patients, paving the way to continued advances in healthcare delivery.

This press release was updated in November 2025 to include all final 2025 ServiceTrak™ Clinical modality award winners following the initial announcement at the ADLM Annual Conference. 

[ARLINGTON, VA — November 2025] — IMV, part of the Science and Medicine Group and the leading market research and business intelligence provider to the clinical laboratory diagnostic industry, has released the complete list of the 2024–2025 IMV ServiceTrak™ Clinical Laboratory Awards. These prestigious awards celebrate industry excellence by recognizing top clinical laboratory manufacturers across multiple instrument categories. 

The initial set of awardees was recognized live at the ADLM Annual Conference in Chicago (July 27–31, 2024), where IMV presented winners in Chemistry, Immunoassay, and Integrated Systems. This updated announcement includes the final modality winners for Hematology, ID/AST, Coagulation, Blood Culture, and Molecular Diagnostics, completing the 2025 award year. 

Each year, laboratory professionals from more than 1,150 clinical testing locations, representing 1,900 instruments, rate their satisfaction with manufacturers in three key performance categories: 

  • Best Customer Satisfaction: highest likelihood of repeat purchase 
  • Best System Performance: highest overall system performance rating 
  • Best Service: highest overall OEM service rating  

The 2024–2025 awards are based on this direct feedback. 

🏆  2024–2025 IMV ServiceTrak™ Clinical Laboratory Award Winners  
(Complete List) 

Chemistry (Announced at ADLM 2024) 

  • Best Service: Roche 
  • Best Customer Satisfaction: Roche 
  • Best System Performance: Roche, QuidelOrtho 

Immunoassay (Announced at ADLM 2024) 

  • Best Customer Satisfaction: Roche 
  • Best Service: bioMérieux, Inc. 
  • Best System Performance: bioMérieux, Inc. 

Integrated Systems (Announced at ADLM 2024) 

  • Best Customer Satisfaction: Roche 
  • Best System Performance: Roche, QuidelOrtho 
  • Best Service: Roche, QuidelOrtho 

Hematology (Final Winners Added November 2025) 

  • Best System Performance: Sysmex America, Inc. 
  • Best Customer Satisfaction: Sysmex America, Inc. 
  • Best Service: Sysmex America, Inc. 

ID/AST 

  • Best System Performance: bioMérieux, Inc. 
  • Best Customer Satisfaction: bioMérieux, Inc. 
  • Best Service: bioMérieux, Inc.; Beckman Coulter 

Coagulation 

  • Best System Performance: Siemens Healthineers; Werfen 
  • Best Customer Satisfaction: Werfen 
  • Best Service: Siemens Healthineers 

Blood Culture 

  • Best System Performance: bioMérieux, Inc. 
  • Best Customer Satisfaction: bioMérieux, Inc. 
  • Best Service: bioMérieux, Inc.; Becton Dickinson 

Molecular Diagnostics 

  • Best System Performance: Roche; bioMérieux, Inc. 
  • Best Customer Satisfaction: Roche; Cepheid 
  • Best Service: Roche 

About IMV’s ServiceTrak™ Program 

IMV, part of Science and Medicine Group, produces an annual series of proprietary ServiceTrak™ Clinical Laboratory reports derived from extensive phone and online interviews with laboratory testing professionals in U.S. hospitals. These reports present an independent analysis of service trends in laboratory diagnostics and include manufacturer ratings for each instrument type. 

Laboratory professionals evaluate their instrument vendors across 38 performance and service attributes, covering the entire system lifecycle—from installation through end-of-life. ServiceTrak has served as the industry’s trusted benchmarking standard for more than 25 years. 

Rating & Award Methodology 

  • Rating Scale: Satisfaction is rated on a 10-point scale (10 = “excellent,” 1 = “very poor”) 
  • Highly Satisfied (%HS): Ratings of 9 or 10 
  • Award Criteria: Awards are given to manufacturers with the highest %HS scores in Customer Satisfaction, System Performance, and Service 
  • Highly Satisfied (%HS): Responses of 9 or 10 are considered “highly satisfied.” 

This evidence-based methodology ensures that ServiceTrak Awards reflect the voice of laboratory customers and highlight the manufacturers delivering the strongest overall experience, performance, and support. 

About IMV 

IMV Medical Information Division, established in 1977, is a trusted marketing research and consulting firm that specializes in the dynamic fields of diagnostic imaging and clinical diagnostics. Our commitment to in-depth market analysis and comprehensive research services empowers clients to excel in strategic planning, enhance customer satisfaction, drive product development, and launch successful sales initiatives. All of IMV’s reports and data solutions are based on primary research by diagnostic imaging experts. As a reliable provider of market intelligence, IMV gives you the comprehensive information you need to stay two steps ahead and make decisions with confidence!  

For media inquires or to learn more about IMV’s ServiceTrak reports, please contact: 

Media Contact
IMV Marketing
(703) 778-3080
www.imvinfo.com
marketing@scienceandmedicinegroup.com   

Arlington, VA — June 2025 — A new survey of 195 diagnostic imaging and clinical lab professionals reveals that tariff policy uncertainty is already changing how providers plan staffing, purchasing, and vendor relationships. The latest Beyond the Bench survey report from IMV, a Science and Medicine Group company, highlights how healthcare organizations are bracing for the financial ripple effects of U.S. tariffs—despite many not yet feeling the full impact. 

 Download the Full Tariff Impact Survey Summary 

While 69% of respondents say tariffs haven’t yet impacted technology investments, the majority expect serious disruption across their operations. Nearly one-third anticipate severe delays in supplies, and 25% expect cost spikes in goods and equipment. Nearly half of respondents say their department has no plan in place to offset rising costs. 

Key Insights: 

  • 33% expect extreme disruption in supply chains due to tariffs 
  • Only 30% have active mitigation plans—most cite hiring pauses, vendor changes, or reduced purchasing 
  • Staffing and reimbursement challenges are already weighing heavily, even before tariffs fully take effect 

These findings reflect an industry already stretched thin—and now preparing for yet another wave of financial pressure. As one respondent noted: “We’re delaying capital purchases and reconsidering our supplier strategy. Costs are rising across the board, and tariffs are only making it harder to plan.” 

Department Leaders Are Weighing Tough Trade-Offs 

Among departments that have begun planning, the top strategies include: 

  • Hiring freezes or staff reductions 
  • Pausing purchases or delaying upgrades 
  • Changing vendors to cut costs 
  • Passing on costs through patient billing 

But with nearly 50% of respondents citing “no plan in place,” this data shows an urgent need for healthcare providers—and their vendors—to align on solutions that address cost control, supply flexibility, and long-term resilience. 

“These results are an early warning signal,” said Richa Singh, VP of Insight Accounts. “Many departments are walking a tightrope between cost pressures, staffing shortages, and policy changes that are still evolving. Vendors who understand these headwinds will be best positioned to support their provider partners with flexible pricing, streamlined procurement, and more strategic partnerships.” 

Join the Science Advisory Board – qualify to participate in future surveys, earn rewards, and shape the future of scientific research:  

 

About Beyond the Bench 

Beyond the Bench is a free monthly intelligence series produced by BioInformatics. Powered by the Science Advisory Board—their proprietary global network of over 55,000 life science and diagnostic professionals—each report delivers timely, survey-based insights on the commercial realities and market shifts facing healthcare providers today. 

Sign up to receive free monthly survey insights: Subscribe to Beyond the Bench   

Service support decisions can significantly impact the performance, uptime, and total cost of ownership of PET systems. According to IMV’s newly released 2025 PET Market Summary Report, original equipment manufacturers (OEMs) continue to dominate the service landscape in 2024, supporting 75% of systems nationwide. However, a deeper look at facility-level data reveals meaningful variation in service strategies—especially among large hospitals and independent PET sites. Understanding these trends is essential for imaging leaders evaluating service options and contract models for their post-warranty systems.